Compare Summit Therapeutics Inc (SMMT) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Summit Therapeutics Inc and Consumer Staples Select Sector SPDR Fund are close in size by market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| SMMT | XLP | |
|---|---|---|
Market Cap | $13.71B | $13.50B |
Volume | 6,173,057 | 14,599,953 |
Sector | Health | — |
52-Week High | $26.38 | $90.00 |
52-Week Low | $12.43 | $75.61 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.41, up 2.09% with bullish technical signals from moving averages and oscillators. The ETF shows strong relative performance, gaining 6.6% year-to-date while consumer discretionary stocks declined. Analyst sentiment is unanimously positive with 100% buy ratings, supported by the fund's low 0.08% expense ratio and defensive positioning during market volatility.
The outlook remains favorable given XLP's defensive characteristics amid economic uncertainty, though rising interest rates pose a headwind. The ETF's focus on household staples provides stability, with dividend income adding to total return potential. Key risks include inflation pressures and consumer spending shifts toward value-oriented options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
